ADC Therapeutics SA
NYSE:ADCT
ADC Therapeutics SA
NYSE:ADCT
Price:
4.14
USD
-2.36%
Market Closed
Market Cap:
$512.9m
Income Statement
Earnings Waterfall
ADC Therapeutics SA
ADC Therapeutics SA
Income Statement
ADC Therapeutics SA
ADC Therapeutics SA
Currency: USD
| Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||||||||||||||
| Interest Expense |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
11
|
0
|
0
|
0
|
37
|
37
|
47
|
60
|
46
|
49
|
51
|
51
|
50
|
50
|
50
|
51
|
|
| Revenue |
2
N/A
|
2
-15%
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
4
N/A
|
17
+350%
|
34
+100%
|
80
+137%
|
94
+17%
|
157
+67%
|
210
+34%
|
182
-13%
|
184
+1%
|
123
-34%
|
70
-43%
|
121
+75%
|
120
-2%
|
123
+3%
|
71
-43%
|
76
+7%
|
77
+2%
|
75
-3%
|
|
| Gross Profit | |||||||||||||||||||||||||
| Cost of Revenue |
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(1)
|
(1)
|
(2)
|
(2)
|
(2)
|
(2)
|
(2)
|
(2)
|
(2)
|
(3)
|
(6)
|
(7)
|
(7)
|
(6)
|
(6)
|
(5)
|
(5)
|
|
| Gross Profit |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
4
N/A
|
16
+348%
|
33
+100%
|
79
+142%
|
92
+17%
|
155
+69%
|
208
+34%
|
180
-13%
|
182
+1%
|
121
-34%
|
67
-44%
|
115
+72%
|
113
-2%
|
116
+3%
|
65
-44%
|
70
+8%
|
72
+3%
|
70
-3%
|
|
| Operating Income | |||||||||||||||||||||||||
| Operating Expenses |
(122)
|
(138)
|
(157)
|
(177)
|
(219)
|
(246)
|
(282)
|
(300)
|
(302)
|
(318)
|
(322)
|
(329)
|
(329)
|
(311)
|
(285)
|
(257)
|
(233)
|
(392)
|
(379)
|
(381)
|
(196)
|
(196)
|
(200)
|
(192)
|
|
| Selling, General & Administrative |
(14)
|
(20)
|
(35)
|
(53)
|
(93)
|
(100)
|
(116)
|
(129)
|
(136)
|
(142)
|
(143)
|
(146)
|
(141)
|
(151)
|
(141)
|
(128)
|
(106)
|
(178)
|
(173)
|
(171)
|
(86)
|
(83)
|
(81)
|
(79)
|
|
| Research & Development |
(106)
|
(118)
|
(122)
|
(124)
|
(140)
|
(146)
|
(165)
|
(170)
|
(164)
|
(175)
|
(177)
|
(182)
|
(186)
|
(176)
|
(160)
|
(145)
|
(127)
|
(211)
|
(204)
|
(210)
|
(110)
|
(113)
|
(119)
|
(113)
|
|
| Depreciation & Amortization |
(2)
|
0
|
0
|
0
|
(2)
|
(0)
|
(1)
|
(1)
|
(3)
|
(2)
|
(1)
|
(1)
|
(2)
|
(1)
|
(1)
|
(2)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Operating Expenses |
0
|
0
|
0
|
0
|
16
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
18
|
18
|
18
|
0
|
(2)
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Operating Income |
(119)
N/A
|
(136)
-14%
|
(157)
-15%
|
(177)
-12%
|
(219)
-24%
|
(246)
-12%
|
(278)
-13%
|
(284)
-2%
|
(270)
+5%
|
(240)
+11%
|
(230)
+4%
|
(174)
+24%
|
(121)
+31%
|
(131)
-8%
|
(103)
+21%
|
(137)
-33%
|
(166)
-21%
|
(277)
-67%
|
(266)
+4%
|
(264)
+1%
|
(131)
+51%
|
(126)
+4%
|
(128)
-2%
|
(123)
+4%
|
|
| Pre-Tax Income | |||||||||||||||||||||||||
| Interest Income Expense |
2
|
2
|
(79)
|
(47)
|
(26)
|
(7)
|
71
|
26
|
10
|
13
|
19
|
24
|
8
|
(23)
|
(42)
|
(44)
|
(35)
|
(70)
|
(63)
|
(61)
|
(38)
|
(35)
|
(40)
|
(42)
|
|
| Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
0
|
7
|
7
|
8
|
8
|
(1)
|
(41)
|
(42)
|
(43)
|
(41)
|
(2)
|
0
|
0
|
0
|
0
|
0
|
0
|
(13)
|
(13)
|
|
| Total Other Income |
2
|
2
|
0
|
(1)
|
(1)
|
(1)
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
6
|
4
|
4
|
4
|
12
|
12
|
12
|
12
|
|
| Pre-Tax Income |
(116)
N/A
|
(133)
-15%
|
(236)
-78%
|
(225)
+5%
|
(246)
-9%
|
(254)
-3%
|
(200)
+21%
|
(251)
-26%
|
(252)
0%
|
(218)
+13%
|
(211)
+3%
|
(191)
+10%
|
(155)
+19%
|
(197)
-27%
|
(185)
+6%
|
(182)
+2%
|
(195)
-8%
|
(343)
-75%
|
(325)
+5%
|
(321)
+1%
|
(156)
+51%
|
(149)
+5%
|
(168)
-13%
|
(166)
+2%
|
|
| Net Income | |||||||||||||||||||||||||
| Tax Provision |
(1)
|
(1)
|
(1)
|
(0)
|
(0)
|
(0)
|
(0)
|
(1)
|
22
|
23
|
24
|
25
|
(1)
|
(2)
|
4
|
3
|
(39)
|
(33)
|
(39)
|
(40)
|
(0)
|
(0)
|
(1)
|
(1)
|
|
| Income from Continuing Operations |
(117)
|
(133)
|
(237)
|
(226)
|
(246)
|
(254)
|
(200)
|
(252)
|
(230)
|
(195)
|
(187)
|
(166)
|
(156)
|
(199)
|
(181)
|
(179)
|
(235)
|
(375)
|
(364)
|
(360)
|
(156)
|
(149)
|
(170)
|
(167)
|
|
| Equity Earnings Affiliates |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(6)
|
(6)
|
(7)
|
(7)
|
(2)
|
0
|
0
|
0
|
|
| Net Income (Common) |
(117)
N/A
|
(133)
-15%
|
(237)
-77%
|
(226)
+5%
|
(246)
-9%
|
(254)
-3%
|
(200)
+21%
|
(252)
-26%
|
(230)
+9%
|
(195)
+15%
|
(187)
+4%
|
(166)
+11%
|
(156)
+6%
|
(199)
-27%
|
(181)
+9%
|
(179)
+2%
|
(240)
-34%
|
(382)
-59%
|
(371)
+3%
|
(367)
+1%
|
(158)
+57%
|
(150)
+5%
|
(170)
-13%
|
(167)
+2%
|
|
| EPS (Diluted) |
-1.52
N/A
|
-1.88
-24%
|
-3.34
-78%
|
-2.94
+12%
|
-3.21
-9%
|
-3.31
-3%
|
-2.61
+21%
|
-3.28
-26%
|
-3
+9%
|
-2.55
+15%
|
-2.44
+4%
|
-2.11
+14%
|
-1.99
+6%
|
-2.45
-23%
|
-2.22
+9%
|
-2.17
+2%
|
-2.94
-35%
|
-4.62
-57%
|
-3.87
+16%
|
-3.5
+10%
|
-1.62
+54%
|
-1.39
+14%
|
-1.49
-7%
|
-1.48
+1%
|
|
Switch to:
Switch to:
See Also
Discover More
